BUDGET IMPACT ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) IN BRAZIL

被引：0
|
作者：
Asano, E. [1 ]
Nita, M. [1 ]
Moellmann-Coelho, A. [2 ]
Rached, R. [1 ]
Donato, B. [3 ]
Rahal, E. [1 ]
机构：
[1] Bristol Myers Squibb SA, Sao Paulo, Brazil
[2] Inst Nacl Canc INCA, Rio De Janeiro, Brazil
[3] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74285-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A262 / A262
页数：1
相关论文
共 50 条
  • [31] Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
    Guilhot, Francois
    Apperley, Jane
    Kim, Dong-Wook
    Bullorsky, Eduardo O.
    Baccarani, Michele
    Roboz, Gail J.
    Amadori, Sergio
    de Souza, Carmino A.
    Lipton, Jeffrey H.
    Hochhaus, Andreas
    Heim, Dominik
    Larson, Richard A.
    Branford, Susan
    Muller, Martin C.
    Agarwal, Prasheen
    Gollerkeri, Ashwin
    Talpaz, Moshe
    BLOOD, 2007, 109 (10) : 4143 - 4150
  • [32] Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice
    DeAngelo, Daniel J.
    Attar, Eyal C.
    LEUKEMIA & LYMPHOMA, 2010, 51 (03) : 363 - 375
  • [33] Outcomes of Second-Line Treatment By Dasatinib in Imatinib-Resistant or - Intolerant Chronic Myeloid Leukemia Patients with and without Comorbidities
    Ionova, Tatyana
    Nikitina, Tatyana
    Kuchma, Galina
    Lomaia, Elza
    Shnaider, Tatyana
    Usacheva, Elena
    Kurbatova, Kira
    BLOOD, 2015, 126 (23)
  • [34] When Evaluating Parameter Uncertainty Is Not Enough: The Case of Dasatinib and Nilotinib for Imatinib-Resistant Chronic Myeloid Leukemia
    Reed, Shelby D.
    VALUE IN HEALTH, 2011, 14 (08) : 1055 - 1056
  • [35] Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients
    Frank, O.
    Brors, B.
    Fabarius, A.
    Li, L.
    Haak, M.
    Merk, S.
    Schwindel, U.
    Zheng, C.
    LEUKEMIA, 2006, 20 (08) : 1400 - 1407
  • [36] An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia
    Agarwal, A.
    Eide, C. A.
    Harlow, A.
    Corbin, A. S.
    Mauro, M. J.
    Druker, B. J.
    Corless, C. L.
    Heinrich, M. C.
    Deininger, M. W.
    LEUKEMIA, 2008, 22 (12) : 2269 - 2272
  • [37] Regulatory network analysis of microRNAs and genes in imatinib-resistant chronic myeloid leukemia
    Soltani, Ismael
    Gharbi, Hanen
    Ben Hassine, Islem
    Bouguerra, Ghada
    Douzi, Kais
    Teber, Mouheb
    Abbes, Salem
    Menif, Samia
    FUNCTIONAL & INTEGRATIVE GENOMICS, 2017, 17 (2-3) : 263 - 277
  • [38] Regulatory network analysis of microRNAs and genes in imatinib-resistant chronic myeloid leukemia
    Ismael Soltani
    Hanen Gharbi
    Islem Ben Hassine
    Ghada Bouguerra
    Kais Douzi
    Mouheb Teber
    Salem Abbes
    Samia Menif
    Functional & Integrative Genomics, 2017, 17 : 263 - 277
  • [39] An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia
    A Agarwal
    C A Eide
    A Harlow
    A S Corbin
    M J Mauro
    B J Druker
    C L Corless
    M C Heinrich
    M W Deininger
    Leukemia, 2008, 22 : 2269 - 2272
  • [40] Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC)
    Giles, Francis J.
    le Coutre, Phillip
    Bhalla, Kapil N.
    Ossenkoppele, Gert
    Alimena, Giuliana
    Haque, Ariful
    Gallagher, Neil
    Kantarjian, Hagop M.
    BLOOD, 2007, 110 (11) : 311A - 312A
12345